secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2026-01-20T23:59:59+00:00
Accession:  0001193125-26-016017
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics announces $46.8M cash, runway into H2 2027, ALSTARS readout Q1 2027
--------------------------------------------------------------------------------

- Cash balance of $46.8M as of Dec 31, 2025 (unaudited), with projected runway into second half of 2027.
- Company expects topline data readout from ALSTARS Phase 2 trial in first quarter of 2027.
- Updates conveyed in letter to stockholders dated January 20, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/0001193125-26-016017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526016017/d48170d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-016017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer